Collaboration and License Agreements - License Agreement with Norgine Pharma UK Limited (Details) $ in Thousands, € in Millions		1 Months Ended		12 Months Ended
	Dec. 15, 2025 EUR (€)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 EUR (€)	Dec. 31, 2025 USD ($)	Dec. 31, 2025 EUR (€)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues | $				$ 68,556		$ 74,205	$ 86,180
License and collaboration revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues | $				63,130		$ 61,370	$ 37,382
Norgine Pharma UK Limited | Norgine Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment received under license agreement		$ 64,300	€ 55
Clinical, regulatory and sales milestone payment	€ 495
External costs (as a percent)	25.00%
Initial payment	€ 55
Maximum aggregate sales milestone payment	€ 495
Norgine Pharma UK Limited | Norgine Agreement | License and collaboration revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenues				$ 64,300	€ 55